Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Abstract Background Targeting the tumor microenvironment (TME) has emerged as a promising strategy in cancer treatment, particularly through the utilization of immune checkpoint blockade (ICB) agents such as PD-1/PD-L1 inhibitors. Despite partial success, the presence of tumor-associated macrophages...

Full description

Bibliographic Details
Main Authors: Shengzhe Jin, Hongfei Wang, Yang Li, Jingwen Yang, Beibei Li, Peishang Shi, Xiangrui Zhang, Xiaowen Zhou, Xiuman Zhou, Xiaoshuang Niu, Menghan Wu, Yahong Wu, Wenjie Zhai, Yuanming Qi, Yanfeng Gao, Wenshan Zhao
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Cell Communication and Signaling
Subjects:
Tumor microenvironment
Immune checkpoint blockade
PD-1/PD-L1
CD47/SIRPα
Radiotherapy
Online Access:https://doi.org/10.1186/s12964-024-01555-4

Internet

https://doi.org/10.1186/s12964-024-01555-4

Similar Items